These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37462295)

  • 1. Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study.
    Gerdes S; Hoffmann M; Asadullah K; Korge B; Mortazawi D; Krüger N; Personke Y; Tabori S; Gomez M; Wegner S; Kreimendahl F; Taut F; Sticherling M
    J Eur Acad Dermatol Venereol; 2023 Jul; ():. PubMed ID: 37462295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
    Gerdes S; Asadullah K; Hoffmann M; Korge B; Mortazawi D; Wegner S; Personke Y; Gomez M; Sticherling M
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1568-1577. PubMed ID: 35569014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
    Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study.
    Gerdes S; Ostendorf R; Süß A; Schadeck T; Taut F; Makuc J; Scharfenberger L; Jacobsen S; Trenkler N; Behrens J; Joks G; Tabori S; Mortazawi D
    J Eur Acad Dermatol Venereol; 2024 Apr; ():. PubMed ID: 38602225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
    Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
    Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison.
    Hampton P; Borg E; Hansen JB; Augustin M
    Psoriasis (Auckl); 2021; 11():123-131. PubMed ID: 34765537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis.
    Diels J; Thilakarathne P; Cameron C; McElligott S; Schubert A; Puig L
    Br J Dermatol; 2020 Aug; 183(2):276-284. PubMed ID: 31652347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
    Gerdes S; Bräu B; Hoffmann M; Korge B; Mortazawi D; Wiemers F; Wegner S; Personke Y; Gomez M; Sticherling M
    J Dermatol; 2021 Dec; 48(12):1854-1862. PubMed ID: 34510527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study.
    Megna M; Balato A; Caccavale S; Cacciapuoti S; Calabrese G; Di Brizzi EV; Di Costanzo L; Manzo R; Marino V; Puca RV; Romano F; Sarno O; Scotto di Luzio G; Lembo S
    J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731081
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
    Kim BS; Jo SJ; Youn S; Reich K; Saadoun C; Chang CL; Yang YW; Huang YH; Tsai TF
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2721-2737. PubMed ID: 37750995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life.
    Berenguer-Ruiz S; Rivera R; Herranz P; De la Cueva P; Hospital M; Ruiz-Genao D; Roustan G; Daudén E; Llamas-Velasco M
    Dermatol Ther; 2022 Oct; 35(10):e15757. PubMed ID: 36190008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials.
    Thilakarathne P; Schubert A; Peterson S; Noel W; Patel BP; Hassan F
    Rheumatol Ther; 2024 Apr; 11(2):457-474. PubMed ID: 38416392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study.
    Puig L; Daudén E; Cuervas-Mons M; Novella C; Guisado C
    J Eur Acad Dermatol Venereol; 2023 Aug; ():. PubMed ID: 37567861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
    Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
    Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
    Armstrong AW; Fitzgerald T; McLean RR; Teeple A; Uy JP; Olurinde M; Rowland K; Guo L; Shan Y; Callis Duffin K
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):629-640. PubMed ID: 36585606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO).
    Travaglini M; Maul JT; Kors C; Zaheri S; Gerwien J; Müller M; Brnabic A; Sabatino S; Schuster C; Tsai TF
    Clin Cosmet Investig Dermatol; 2023; 16():2971-2983. PubMed ID: 37881205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.